<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Inherited disorders of the complement system</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Inherited disorders of the complement system</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Inherited disorders of the complement system</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">M Kathryn Liszewski, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John P Atkinson, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter H Schur, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jordan S Orange, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anna M Feldweg, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 10, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Inherited complete deficiencies of complement components are rare disorders that most often predispose to bacterial infections and/or systemic lupus erythematosus (SLE). They are associated with predictable defects in complement-dependent function, as the affected individual loses not only the activity of the deficient protein, but also the functions of the proteins that follow in the cascade. Additionally, increasing recognition of heterozygous deficiency (ie, haploinsufficiency) due to loss-of-function mutations in regulators and gain-of-function mutations in activators has led to new disease associations [<a href="#rid1">1</a>].</p><p>Inherited complement deficiencies are classified into two general categories: integral component defects and regulatory component defects [<a href="#rid2">2</a>]. Inherited disorders of the complement system will be reviewed here. Acquired disorders and the general evaluation of the complement system are discussed separately. (See  <a class="medical medical_review" href="/d/html/3930.html" rel="external">"Acquired disorders of the complement system"</a> and  <a class="medical medical_review" href="/d/html/3920.html" rel="external">"Overview and clinical assessment of the complement system"</a> and  <a class="medical medical_review" href="/d/html/3968.html" rel="external">"Complement pathways"</a>.)</p><p class="headingAnchor" id="H35196879"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H2245860"><span class="h2">Deficiencies in an integral component of the activating cascades</span><span class="headingEndMark"> — </span>Inherited disorders of complement components present predominantly with recurrent bacterial infections and/or systemic lupus erythematosus (SLE) [<a href="#rid3">3-5</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infections</strong> – Patients with deficiency of a complement pathway protein are susceptible to recurrent sinopulmonary bacterial infections, bacteremia, and/or meningitis. The pathogens most commonly implicated are encapsulated bacteria, such as <em>Streptococcus pneumoniae</em>, <em>Haemophilus influenzae</em> type b, and <em>Neisseria meningitidis</em>. (See  <a class="medical medical_review" href="/d/html/5949.html" rel="external">"Approach to the child with recurrent infections"</a> and  <a class="medical medical_review" href="/d/html/3908.html" rel="external">"Approach to the adult with recurrent infections"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Autoimmunity</strong> – The most common autoimmune disorder by far among patients with a total complement deficiency is SLE [<a href="#rid6">6-18</a>]. SLE commonly develops in individuals deficient in an early component of the classical pathway (ie, C1q, C1r, C1s, C4, and C2). (See  <a class="medical medical_review" href="/d/html/6420.html" rel="external">"Childhood-onset systemic lupus erythematosus (SLE): Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H2245866"><span class="h2">Deficiencies in regulatory proteins</span><span class="headingEndMark"> — </span>Patients with deficiencies of certain complement regulatory proteins develop specific disorders resulting from undesirable complement activation. Inherited complete deficiencies of regulators lead to consumption of multiple components in a pathway. In contrast, haploinsufficiency leads to an excessive local inflammatory response at a site of injury or debris accumulation and commonly requires an underlying trigger, such as endothelial cell damage. As examples, heterozygous deficiency of C1 inhibitor causes hereditary angioedema, an autosomal dominant disorder, while haploinsufficiency of factor H predisposes to atypical hemolytic uremic syndrome (aHUS) and age-related macular degeneration (AMD) [<a href="#rid19">19-23</a>]. Homozygous factor H or factor I deficiency results in alternative pathway activation, cleavage and consumption of C3 and factor B, and increased susceptibility to pyogenic infections. Heterozygous deficiency of factor I is also associated with both aHUS and AMD [<a href="#rid19">19,24</a>]. (See <a class="local">'Abnormalities in regulatory proteins'</a> below.)</p><p class="headingAnchor" id="H2"><span class="h1">CLASSICAL PATHWAY DEFICIENCIES</span></p><p class="headingAnchor" id="H3"><span class="h2">Genetics and epidemiology</span><span class="headingEndMark"> — </span>Most inherited disorders of the integral classical pathway components are transmitted as autosomal codominant (recessive) traits. Two abnormal alleles must be present to yield complete deficiency, and, in most cases, only patients with a complete deficiency are symptomatic. Heterozygous deficiencies in which individuals have 50 percent of a component are almost always asymptomatic (eg, parents of children with C3 or C5 deficiency). The association of partial C4 deficiency with systemic lupus erythematosus (SLE) [<a href="#rid25">25</a>] reflects the presence of a C4A null gene on the associated human leukocyte antigen (HLA) B8, DR3 conserved, extended haplotype [<a href="#rid26">26</a>]. Other extended major histocompatibility complex (MHC) haplotypes with null C4A or null C4B genes are not increased among patients. (See <a class="local">'C4 deficiency'</a> below.)</p><p class="headingAnchor" id="H4"><span class="h2">Indications for screening</span><span class="headingEndMark"> — </span>Screening for a classical complement pathway defect as a cause of recurrent infections is indicated in patients with any of the following [<a href="#rid27">27</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Recurrent, unexplained pyogenic infections in the setting of normal white blood cell counts and immunoglobulin levels in children (ie, no obvious cause)</p><p class="bulletIndent1"><span class="glyph">●</span>Recurrent neisserial infections at any age</p><p class="bulletIndent1"><span class="glyph">●</span>Multiple family members with neisserial infections</p><p></p><p>In addition, it is reasonable to check, at least once, a total hemolytic complement (THC or CH50) in any patient with SLE. This is particularly relevant in those with familial lupus or subacute cutaneous lupus in whom C2 deficiency should be considered.</p><p class="headingAnchor" id="H5"><span class="h2">Screening CH50 and interpretation</span><span class="headingEndMark"> — </span>The total hemolytic complement (THC or CH50) assay is a reliable screen for a homozygous deficiency in an integral component of the classical pathway.</p><p>Care must be taken in the handling of serum specimens since complement hemolytic activity is unstable and heat labile and can be reduced after a few hours at room temperature. Also, another cause for low- or zero-complement activity in patients is cold activation by immune complexes and/or cryoglobulins [<a href="#rid28">28</a>]. (See  <a class="medical medical_review" href="/d/html/3920.html" rel="external">"Overview and clinical assessment of the complement system"</a>.)</p><p>The CH50 measures the capacity of a patient's serum to lyse sheep erythrocytes coated with rabbit antibody directed against antigens on the red blood cell (RBC) membrane. All nine components of the classical pathway (C1 through C9) are required for a normal CH50, which is 150 to 250 units/mL in a commonly used assay system. For example, a CH50 of 200 units/mL means that a serum sample diluted 1:200 lysed 50 percent of the antibody-coated sheep erythrocytes (measured by hemoglobin release) in the test mixture.</p><p>An elevated CH50 has no specific clinical significance other than to reflect that complement proteins increase as part of the acute-phase response.</p><p>Individuals with heterozygous deficiency will generally have a normal CH50 because the level of a component must be reduced by more than 50 percent before the CH50 is altered. Heterozygous C2 deficiency is one exception. C2 is the limiting component in a CH50 determination, and patients with heterozygous C2 deficiency tend to have mildly low CH50 values. (See <a class="local">'C2 deficiency'</a> below.)</p><p>A complete deficiency of any one integral component gives an undetectable CH50 value (often reported as less than some specified low value), with the exception of C9 deficiency. Homozygous C9 deficiency, which is most often reported in Japanese, Korean, and Chinese individuals, gives a low, but detectable CH50 titer [<a href="#rid29">29,30</a>]. (See <a class="local">'C5-C9 deficiency'</a> below.)</p><p>If a patient is found to have a very low or undetectable CH50, the first step is to repeat the test. If it is low again, then the next step is the measurement of specific complement proteins. C2 deficiency is most commonly observed on the HLA-B18, DR2 extended haplotype. Heterozygotes thus constitute a little over 1 percent of European White individuals, and homozygotes are seen in approximately 1 in 20,000 individuals of this population [<a href="#rid9">9</a>]. If C2 is normal, then a complete deficiency of C1q, C4, C3, or a membrane attack component (C5, C6, C7, C8, or C9) should be tested next. Complete deficiencies of these components (other than C2) have only been described in approximately 30 to 100 individuals each.</p><p>Another approach is to perform an alternative pathway (AH50) assay. This test, although not as widely available, can be performed in referral laboratories. A neisserial infection is the most common indication for this diagnostic approach. If AH50 is also very low or undetectable, then the deficiency is most likely of C3, C5, C6, C7, C8, or C9, as these components overlap in CH50 and AH50 assays. If more than one component is low, the problem is almost always an acquired deficiency or lack of a regulator  (<a class="graphic graphic_figure graphicRef56374" href="/d/graphic/56374.html" rel="external">figure 1</a>).</p><p class="headingAnchor" id="H2768570194"><span class="h2">Genetic screening</span><span class="headingEndMark"> — </span>Whole genome, whole exome, and targeted deep sequencing are increasingly utilized for the specific diagnosis of complete or partial (haploinsufficiency) complement deficiencies. Examples of the latter are those for atypical hemolytic uremic syndrome (aHUS) and age-related macular degeneration (AMD). Likewise, testing for copy number variation (CNV) is becoming more common. It is likely that all patients with SLE will be evaluated for CNV of C4 at the time of diagnosis [<a href="#rid18">18</a>]. Relative to aHUS, many centers now perform targeted deep sequencing on 6 to 12 genes for patients with aHUS to facilitate diagnosis, decide on treatment, and evaluate for transplantation in patients with a history of a thrombotic microangiopathy.</p><p class="headingAnchor" id="H6"><span class="h2">Specific disorders</span></p><p class="headingAnchor" id="H7"><span class="h3">C1 deficiency</span><span class="headingEndMark"> — </span>Although any one of the three subcomponents (C1q, C1r, or C1s) of the C1 complex may be deficient, the most common inherited deficiency is of C1q.</p><p class="bulletIndent1"><span class="glyph">●</span>More than 90 percent of C1q-deficient individuals develop SLE, and they may also have recurrent bacterial infections. Most of these patients have typical clinical and serologic findings of SLE. (See  <a class="medical medical_review" href="/d/html/6420.html" rel="external">"Childhood-onset systemic lupus erythematosus (SLE): Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A deficiency of the serine protease C1r or C1s also results in the development of SLE, with prominent renal and cutaneous sequelae. C1r or C1s homozygous deficiency is exceptionally rare (ie, fewer than 10 cases reported). Some of these patients have deficiencies of both C1r and C1s, consistent with the close linkage of the genes for these two homologous proteins.</p><p></p><p class="headingAnchor" id="H8"><span class="h3">C4 deficiency</span><span class="headingEndMark"> — </span>Total deficiency of C4 is rare. Approximately 80 percent of patients present with SLE that is often severe and begins at an early age.</p><p>In contrast, partial deficiency of C4 is common and is part of the HLA-B8, DR3 extended haplotype that also predisposes to the development of SLE [<a href="#rid17">17,25,31</a>]. A borderline or low C4 (with normal C3) is observed in 1 to 3 percent of the White population, and most of these individuals are asymptomatic. Among White persons with SLE, 5 to 10 percent will be C4A deficient. It is unclear whether the C4A deficiency alone or some other gene on the 1.4 to 5 Mb haplotype is also responsible. Complete C4A deficiency (missing both C4A genes, reflecting homozygosity for HLA-B8, DR3) increases one's risk of SLE. Approximately 1 to 2 percent of the White population lacks both copies of C4A and may have C4 serum concentrations as low as half the usual normal range.</p><p>C4 is encoded as two highly polymorphic genes, C4A and C4B, which are located in the MHC on chromosome 6. Fifty to 65 percent of the population carries two C4A and two C4B genes. In the rest of the population, at least one or more C4A and/or C4B gene(s) are deleted or duplicated. An individual may carry one to eight functional C4 genes. These differences in gene number are referred to as "copy number variation."</p><p>The more null (nonexpressed) C4 alleles an individual possesses, the greater the predisposition to SLE. Genetic testing is required to determine the number and type of C4 genes. In the future, there will be genetic tests to allow for rapid assessment of gene copy number, although at present this is usually performed for research purposes. Levels of C4 may be 0, 25, 50, or 75 percent of normal depending upon whether the individual inherits four, three, two, or one nonexpressed allele(s), respectively. In these individuals, C4 is borderline low throughout life, and, if SLE develops, C4 drops even lower. Such patients will continue to show low or low-normal total C4, even with successful treatment of the disease. This can cause confusion when a patient with SLE is treated and there is resolution of clinical symptoms and C3 levels normalize but C4 levels remain low. There are two explanations for this picture:</p><p class="bulletIndent1"><span class="glyph">●</span>The disease is in remission and patient is C4A deficient (lacks expressed C4A genes, for example) such that the patient will always have a low C4.</p><p></p><p class="bulletIndent1"><strong>or</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There is ongoing but reduced classical pathway activation. (See  <a class="medical medical_review" href="/d/html/4668.html" rel="external">"Clinical manifestations and diagnosis of systemic lupus erythematosus in adults"</a>.)</p><p></p><p class="headingAnchor" id="H2245115"><span class="h4">Low C4 in the patient with SLE</span><span class="headingEndMark"> — </span>The interpretation of a low C4 in a patient with systemic lupus erythematosus (SLE) can be complicated, as noted above. Reduced levels may be due to consumption as well as to deficiency of one or more alleles. Both causes may be present in a given patient. The underlying mechanisms can sometimes be distinguished by the following observations:</p><p class="bulletIndent1"><span class="glyph">●</span>Consumption is associated with a reduction in multiple complement components. As an example, low C4, C2, and C3 indicate consumption. In addition, consumption fluctuates over time.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inherited complement deficiency is characterized by the fixed absence of a single complement component.</p><p></p><p>If there is still uncertainty, a blood sample can be sent to a commercial laboratory specializing in complement tests. To determine the number of C4 alleles at the deoxyribonucleic acid (DNA) level, the sample would need to be sent to a research laboratory. HLA typing can determine if the patient carries the HLA-B8, DR3 haplotype. Definitive reviews have been published on determining copy number of C4 genes in a large number of normal controls and SLE patients [<a href="#rid25">25,32-34</a>]. Tests to measure C4 and C3 antigen levels in the plasma or serum are widely available, reliable, and can be obtained within a few hours. Assessment of C4 and C3 can be useful in diagnosing and monitoring the clinical status of patients with SLE. In addition, assessment of complement activation products, such as C3a, C5a, and sC5b-9, may also prove useful, although proper handling of blood samples poses a major technical challenge, and it is often difficult to standardize sample collection adequately. The more stable end products of complement activation, cell-bound C4d and C3d, are covalently bound to RBCs, platelets, and/or peripheral blood B and T lymphocytes. Several reports suggest that monitoring C4d bound to RBCs and lymphocytes is superior in diagnosing and monitoring a response to therapy in patients with SLE compared with following C4 and C3 antigen levels [<a href="#rid35">35,36</a>]. However, additional investigations (including longer-term studies) are needed before such tests can be routinely used, and they will likely not replace C3 and C4 antigen levels. (See  <a class="medical medical_review" href="/d/html/4675.html" rel="external">"Overview of the management and prognosis of systemic lupus erythematosus in adults", section on 'Assessment of disease activity'</a>.)</p><p class="headingAnchor" id="H2245128"><span class="h4">Other associated disorders</span><span class="headingEndMark"> — </span>Deficiency of C4A or C4B as parts of various extended MHC haplotypes has also been associated with the development of other disorders. These include scleroderma, immunoglobulin A (IgA) nephropathy, immunoglobulin A vasculitis (IgAV; Henoch-Schönlein purpura [HSP]), childhood diabetes mellitus, chronic forms of noninfectious hepatitis, membranous nephropathy, and subacute sclerosing panencephalitis.</p><p>One report identified a strikingly high frequency of capillary leak syndrome (CLS) in children undergoing cardiac surgery with cardiopulmonary bypass who were C4A null (ie, no C4A protein in their blood) [<a href="#rid37">37</a>]. If these patients were given C4A-rich blood, only 3 of 58 developed CLS. If they were given blood lacking C4A, 56 (97 percent) developed CLS. The authors are unaware of a confirmatory report. (See  <a class="medical medical_review" href="/d/html/3919.html" rel="external">"Idiopathic systemic capillary leak syndrome"</a>.)</p><p class="headingAnchor" id="H9"><span class="h3">C2 deficiency</span><span class="headingEndMark"> — </span>Homozygous, complete deficiency of C2 occurs mainly in White individuals at a frequency of approximately 1 in 20,000 [<a href="#rid9">9,27</a>]. Twenty to 60 percent of females with C2 deficiency present with an SLE-like illness [<a href="#rid9">9,38,39</a>]. (See  <a class="medical medical_review" href="/d/html/4668.html" rel="external">"Clinical manifestations and diagnosis of systemic lupus erythematosus in adults"</a>.)</p><p>Another presentation, especially in early childhood, is recurrent pyogenic infections with encapsulated bacteria, such as <em>S. pneumoniae</em>, <em>H. influenza</em> type b, and <em>N. meningitidis</em> [<a href="#rid38">38,40</a>].</p><p>C2 deficiency is also sometimes associated with immunoglobulin G (IgG) subclass deficiency. Other disease associations include discoid lupus erythematosus, polymyositis, glomerulonephritis, Hodgkin lymphoma, vasculitis, and IgAV. (See  <a class="medical medical_review" href="/d/html/5949.html" rel="external">"Approach to the child with recurrent infections"</a> and  <a class="medical medical_review" href="/d/html/3948.html" rel="external">"Inborn errors of immunity (primary immunodeficiencies): Overview of management"</a> and  <a class="medical medical_review" href="/d/html/3914.html" rel="external">"Primary humoral immunodeficiencies: An overview"</a>.)</p><p>Tests for antinuclear antibodies may be positive in a low titer and often demonstrate a speckled pattern. Tests for antibodies to double-stranded DNA are usually negative. However, more than 50 percent of patients have antibodies to the Ro (SS-A) antigen. (See  <a class="medical medical_review" href="/d/html/1818.html" rel="external">"The anti-Ro/SSA and anti-La/SSB antigen-antibody systems"</a>.)</p><p>Partial C2 deficiency appears to have no clinical significance in most individuals, and its frequency does not appear to be increased among patients with SLE [<a href="#rid9">9,10,41</a>]. It is sometimes detected because it can yield a low CH50, as previously discussed. (See <a class="local">'Screening CH50 and interpretation'</a> above.)</p><p>Patients may also have a combination of multiple autoimmune phenomena, especially various cutaneous manifestations, and pyogenic infections. In one such case, a patient appeared to respond to treatment with <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, although IgG declined, requiring <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> replacement therapy [<a href="#rid39">39</a>].</p><p class="headingAnchor" id="H10"><span class="h3">C3 deficiency</span><span class="headingEndMark"> — </span>Complete deficiency of C3, the major opsonin of the complement system, results in severe, recurrent infections with encapsulated bacteria that begin shortly after birth [<a href="#rid6">6,27</a>]. Patients with C3 deficiency are particularly prone to infections with the pneumococcus and, less frequently, <em>H. influenza</em> or <em>N. meningitidis</em>.</p><p>Children who survive these infections subsequently may develop problems secondary to excess immune complex formation, especially glomerulonephritis. (See  <a class="medical medical_review" href="/d/html/3055.html" rel="external">"Membranoproliferative glomerulonephritis: Classification, clinical features, and diagnosis"</a>.)</p><p>Partial C3 deficiency, which results in one-half the normal serum level of C3, appears to have no clinical significance.</p><p>Total deficiency of factors H or I gives rise to a secondary C3 deficiency. A deficiency of one of these regulatory proteins and a C3 or C4 nephritic factor (autoantibody to a C3 convertase, C3bBb or C4b2a) should be considered in the evaluation of a child with presumed C3 deficiency [<a href="#rid42">42,43</a>]. (See <a class="local">'Factor H, factor I, and membrane cofactor protein'</a> below.)</p><p class="headingAnchor" id="H11"><span class="h3">C5-C9 deficiency</span><span class="headingEndMark"> — </span>A deficiency of a component of the membrane attack complex (MAC, C5-C9) is associated with infection by <em>Neisseria</em> species (especially the meningococcus), which are characteristically of an unusual serotype (for reasons that are unclear). Neisserial infections in these patients with a deficient protein of the MAC tend to be recurrent and clinically mild to moderate, with a low (approximately 2 percent) mortality rate [<a href="#rid6">6,44-54</a>]. Patients are otherwise healthy in most cases. (See  <a class="medical medical_review" href="/d/html/1300.html" rel="external">"Clinical manifestations of meningococcal infection"</a> and  <a class="medical medical_review" href="/d/html/1276.html" rel="external">"Microbiology and pathobiology of Neisseria meningitidis"</a> and  <a class="medical medical_review" href="/d/html/1298.html" rel="external">"Epidemiology of Neisseria meningitidis infection"</a> and  <a class="medical medical_review" href="/d/html/4983.html" rel="external">"Gonococcal infection in the newborn"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>In the United States, C5, C6, or C8 deficiency is the most common [<a href="#rid44">44-46,50-53</a>]. C6 deficiency is usually reported in African Americans with South African ancestry [<a href="#rid45">45,46</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>C7 deficiency has been reported worldwide [<a href="#rid47">47-49,55-58</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>C9 deficiency is almost always observed in people of Japanese or Korean ancestry, in whom it is inherited as an autosomal recessive trait [<a href="#rid29">29,30</a>]. It is one of the most frequent genetic disorders in the Japanese population. It is associated with lower rates of mortality compared with complement-normal patients, so this variant may confer an evolutionary advantage in the heterozygous state [<a href="#rid29">29</a>]. C9 deficiency is a less severe defect because cells can still be lysed by C5b-8, albeit with less efficiency than if C9 is present.</p><p></p><p>As mentioned previously, a complete deficiency of any one component of the MAC gives an undetectable CH50 value. The exception is C9 deficiency, which gives a low but detectable CH50 titer. The CH50 should be the initial screening test. The usual clinical indication is recurrent neisserial infections. If the CH50 is zero or very low, then the specific deficiency is diagnosed by measuring levels of C5, C6, C7, C8, and C9. C6 should be measured first in African American patients, while C5 and C8 should be checked initially in White individuals and C9 in patients of Japanese, Korean, or Chinese descent.</p><p class="headingAnchor" id="H12"><span class="h1">ALTERNATIVE PATHWAY DEFICIENCIES</span><span class="headingEndMark"> — </span>An inherited defect in a component of the alternative pathway is rare. Affected patients present with serious neisserial and pneumococcal infections [<a href="#rid27">27</a>]. An alternative pathway (AH50) assay is a screen for such a deficiency. If very low or undetectable, individual components (factor B, factor D, or properdin) can be assessed. Recall that if the CH50 is also low, the defect must be in C3 or a terminal pathway component. (See  <a class="medical medical_review" href="/d/html/3920.html" rel="external">"Overview and clinical assessment of the complement system"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Properdin deficiency is the only one of the early components of the alternative pathway for which more than a few cases have been reported [<a href="#rid27">27,59-62</a>]. Properdin-deficient individuals have no activity of the alternative pathway in most assay systems  (<a class="graphic graphic_figure graphicRef61780" href="/d/graphic/61780.html" rel="external">figure 2</a>) [<a href="#rid63">63</a>]. This disorder affects one-half of males within an affected family because the gene is on the X chromosome [<a href="#rid6">6,59,64</a>]. <em>N. meningitidis</em> is the most frequently implicated infection and is often of an unusual serotype. Thus, a male child with a family history of neisserial meningitis should be evaluated for properdin deficiency. Recurrent otitis media and pneumonia have also been reported [<a href="#rid64">64</a>]. The mortality rate for properdin deficiency is in the range of 34 to 63 percent [<a href="#rid59">59,63</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A small number of patients (&lt;5) with factor D deficiency have been reported [<a href="#rid27">27,63,65</a>]. To date, the disorder has been observed in children of consanguineous parents, and all have developed meningococcal sepsis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The first recognized case of factor B deficiency was reported in 2013 in a 32-year-old woman with nonconsanguineous parents who had experienced several serious pneumococcal and meningococcal infections since the age of two years [<a href="#rid27">27,66</a>]. One parent carried a frameshift mutation and the other a nonsense mutation. Heterozygous family members did not have a history of recurrent infections.</p><p></p><p>Factor H and factor I are sometimes included in the discussions of the alternative pathway, although they are more accurately classified as regulatory proteins. (See <a class="local">'Factor H, factor I, and membrane cofactor protein'</a> below.)</p><p class="headingAnchor" id="H13"><span class="h1">LECTIN PATHWAY DEFICIENCIES</span><span class="headingEndMark"> — </span>Inherited defects in components of the lectin pathway include deficiencies of mannan-binding lectin-associated protease 2 (MASP2), ficolin 3 [<a href="#rid67">67,68</a>], and the 3MC syndrome [<a href="#rid69">69-71</a>].</p><p class="headingAnchor" id="H15"><span class="h2">MASP2 deficiency</span><span class="headingEndMark"> — </span>A deficiency of MASP2 has been described [<a href="#rid72">72</a>]. Severe pneumococcal pneumonia and immune disorders, including ulcerative colitis and erythema multiforme bullosum, were reported in one patient with this abnormality. Another study found a deficiency of MASP2 was associated with an increased risk of fever and neutropenia in pediatric patients treated with chemotherapy for cancer [<a href="#rid73">73</a>].</p><p class="headingAnchor" id="H16"><span class="h2">Ficolin 3 deficiency</span><span class="headingEndMark"> — </span>A patient homozygous for a frameshift mutation of the ficolin 3 gene (<em>FCN3</em>) resulting in the absence of serum ficolin 3 has been reported [<a href="#rid27">27,74</a>]. This patient had recurrent severe pulmonary infections since early childhood that resulted in bronchiectasis, pulmonary fibrosis, and progressive obstructive lung disease. He also had recurrent warts on his fingers and brain abscesses beginning in early adulthood. He had normal activity of the three complement pathways as routinely measured clinically (using mannan-binding lectin [MBL] to trigger the lectin pathway), but lacked complement deposition on acetylated structures. His heterozygous parents and a sibling were healthy, which suggests an autosomal recessive pattern of inheritance. Ficolin 3 deficiency was also reported in a 50-year-old male suffering from membranous nephropathy and an 11-month-old male infant following surgery to repair a congenital heart defect [<a href="#rid75">75</a>].</p><p class="headingAnchor" id="H41072387"><span class="h2">3MC syndrome</span><span class="headingEndMark"> — </span>Homozygous mutations in either of two genes (collectin subfamily member 11 [<em>COLEC11</em>] and MBL-associated serine protease 1 [<em>MASP1</em>]), encoding for distinct but related secreted proteins involved in lectin pathway activation, can be responsible for this developmental disorder. It features facial dysmorphic traits (hypertelorism, eyebrow abnormalities, cleft lip and palate, and other developmental, growth, and cognitive impairments). The MASP protein is required for lectin pathway activation, and CL-K1 (lectin-like protein of the <em>COLEC11</em> gene) has a carbohydrate-recognition domain. Thus, early in life, these proteins are important for development, and then, at birth, they are involved in host defense [<a href="#rid70">70,71</a>].</p><p class="headingAnchor" id="H17"><span class="h1">ABNORMALITIES IN REGULATORY PROTEINS</span><span class="headingEndMark"> — </span>Clinically important deficiencies/defects of complement regulatory proteins include those of C1 inhibitor, factor H, factor I, membrane cofactor protein (MCP), complement receptor 3 (CR3), decay-accelerating factor (DAF), and CD59. (See  <a class="medical medical_review" href="/d/html/3967.html" rel="external">"Regulators and receptors of the complement system"</a>.)</p><p class="headingAnchor" id="H19"><span class="h2">C1 inhibitor deficiency</span><span class="headingEndMark"> — </span>Deficiency of C1 inhibitor gives rise to hereditary angioedema, which is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/8098.html" rel="external">"Hereditary angioedema (due to C1 inhibitor deficiency): Pathogenesis and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/8103.html" rel="external">"Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis"</a> and  <a class="medical medical_review" href="/d/html/8100.html" rel="external">"Hereditary angioedema (due to C1 inhibitor deficiency): General care and long-term prophylaxis"</a> and  <a class="medical medical_review" href="/d/html/8104.html" rel="external">"Hereditary angioedema: Acute treatment of angioedema attacks"</a>.)</p><p class="headingAnchor" id="H20"><span class="h2">Factor H, factor I, and membrane cofactor protein</span><span class="headingEndMark"> — </span>Plasma factors H and I regulate C3 and a complete deficiency of either factor allows the alternative pathway to fire to exhaustion and thereby consume C3 [<a href="#rid4">4,5,76</a>].</p><p>As a result, afflicted individuals exhibit symptoms and findings similar to that of C3-deficient patients (ie, recurrent infections). (See <a class="local">'C3 deficiency'</a> above.)</p><p>In homozygous factor H or factor I deficiency, factor B is also low, while it is normal in isolated C3 deficiency. Protein levels of factor H or factor I should be assessed in a patient with very low C3 levels, especially if factor B is also reduced.</p><p>Alternative pathway dysregulation due to haploinsufficiency has also been associated with the pathogenesis of hematopoietic cell transplant (HCT) associated thrombotic microangiopathy (TMA) in children [<a href="#rid77">77</a>]. In this case study, a high prevalence of genetic variations in the factor H gene cluster as well as the presence of factor H autoantibodies correlated with post-HCT TMA.</p><p>Additionally, heterozygous deficiency of factors H or I predispose to atypical (nondiarrheal) hemolytic uremic syndrome (aHUS) and age-related macular degeneration (AMD). Heterozygous deficiency of MCP (CD46) also predisposes to aHUS:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>aHUS</strong> – Heterozygous mutations in the genes for factor H, factor I, as well as those for MCP (CD46), have been associated with aHUS  (<a class="graphic graphic_table graphicRef140105" href="/d/graphic/140105.html" rel="external">table 1</a>) [<a href="#rid24">24,78-82</a>]. Approximately 50 percent of patients with aHUS have a defect in one of these three complement regulatory proteins. In addition, these patients may have autoantibodies to factor H or a gain-of-function mutation in C3 or factor B. This is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/6084.html" rel="external">"Complement-mediated hemolytic uremic syndrome in children"</a>.)</p><p></p><p class="bulletIndent1">More than 60 disease-associated mutations in the gene for MCP have now been identified [<a href="#rid80">80</a>]. These heterozygous dysfunctional rare variants in MCP account for 10 to 20 percent of aHUS patients. Complete deficiency of MCP has only been reported in a few (&lt;10) cases. These patients presented with aHUS, and several had hypogammaglobulinemia in association with a T helper cell defect [<a href="#rid83">83</a>]. In the mouse, knockout of a widely expressed protein related to MCP (known as Crry) led to chronic alternative pathway activation on cells and was embryonic lethal but could be rescued by maternal C3, factor B, factor D, or properdin deficiency [<a href="#rid84">84</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>AMD</strong> – An association exists between a polymorphism in factor H and AMD. The 402H variant (the uncommon allele) is carried by approximately 30 percent of the White population. This variant increases the risk of developing AMD by 1.5- to 3-fold if heterozygous and up to 10-fold if homozygous. It accounts for approximately 50 percent of the attributable genetic risk for AMD. This association is most consistent with a decrease in functional activity of the variant in controlling alternative pathway activation in the retina. Rare variants in factor H, factor I, C3, and factor B have been shown to predispose strongly to AMD. Up to 5 percent of advanced AMD patients carry a rare variant in factor I. Such mutations tend to associate with early age of onset (&lt;70 years) and more severe disease [<a href="#rid19">19,85-87</a>]. Relative to the regulators, it is a loss of function, while, in the integral components of the alternative pathway, it is a gain of function. Of note, many of the gain-of-function variants in C3 are in the site where regulators attach to inactivate C3b. Thus, variants that increase the activity of the alternative pathway predispose to AMD.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>C3 glomerulopathies and membranoproliferative glomerulonephritis (types 1 to 3)</strong> – Abnormal deposition of C3 fragments has been increasingly described as a consequence of genetic or acquired defects causing over activation of the alternative pathway activation [<a href="#rid88">88,89</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Elevated serum levels of factor H</strong> – In two reports, high levels of factor H resulted in reduced complement activity and increased susceptibility to meningococcal disease [<a href="#rid90">90,91</a>]. The responsible defect was an alteration in the promoter region of the gene encoding factor H.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>HELLP</strong> – Like aHUS, the pregnancy-related HELLP (ie, <strong>h</strong>emolysis with a microangiopathic blood smear, <strong>e</strong>levated <strong>l</strong>iver enzymes, and a <strong>l</strong>ow <strong>p</strong>latelet count) syndrome features endothelial cell damage, although the liver rather than the kidney appears to be the main organ undergoing injury. In one series, heterozygous mutations in complement regulators factor I, factor H, and MCP were observed in approximately 50 percent of severe HELLP patients, but, in another series, it was much lower [<a href="#rid92">92-95</a>]. The etiology of HELLP remains enigmatic, and further studies in a complement/HELLP connection are required. (See  <a class="medical medical_review" href="/d/html/6778.html" rel="external">"HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets)"</a>.)</p><p></p><p class="headingAnchor" id="H21"><span class="h2">Complement receptor 3</span><span class="headingEndMark"> — </span>An inherited deficiency of complement receptor 3 (CR3 or CD11b/CD18), an integrin that binds inactive iC3b as well as other noncomplement ligands, causes recurrent and severe bacterial (<em>Staphylococcus aureus</em> and/or <em>Pseudomonas</em>) infections. This condition, known as leukocyte-adhesion deficiency syndrome I (CD11/CD18 deficiency), may present shortly after birth with delayed separation of the umbilical cord and development of omphalitis. (See  <a class="medical medical_review" href="/d/html/3918.html" rel="external">"Leukocyte-adhesion deficiency"</a>.)</p><p class="headingAnchor" id="H22"><span class="h2">Decay-accelerating factor</span><span class="headingEndMark"> — </span>A deficiency of decay-accelerating factor (DAF, CD55) caused by a biallelic loss-of-function mutation has been linked to early-onset protein-losing enteropathy and thrombosis (the CHAPLE syndrome) [<a href="#rid96">96</a>]. (See  <a class="medical medical_review" href="/d/html/3930.html" rel="external">"Acquired disorders of the complement system", section on 'Somatic mutation of a complement gene'</a>.)</p><p class="headingAnchor" id="H23"><span class="h1">CARE OF THE COMPLEMENT-DEFICIENT PATIENT</span></p><p class="headingAnchor" id="H24"><span class="h2">Vigilance for early signs of serious infection</span><span class="headingEndMark"> — </span>Patients with complement deficiencies who have experienced one or more serious infections should wear a medical identification badge identifying their specific condition.</p><p>Patients should be instructed to seek medical assistance for high fevers, stiff neck, severe headache, severe myalgias, or petechial and/or purpuric rash. Once they have had meningococcal disease, most patients are very cognizant of the symptoms.</p><p class="headingAnchor" id="H25"><span class="h2">Vaccination</span><span class="headingEndMark"> — </span>Patients with complement deficiency may receive all routine bacterial and viral vaccines safely and are not at increased risk for adverse reactions to live-viral vaccines. It is important to ensure that patients are vaccinated against those diseases for which they are at increased risk, especially the meningococcus and the pneumococcus.</p><p>When immunizing patients with complement deficiency, "conjugate" vaccines are preferred over pure polysaccharide vaccines.</p><p class="bulletIndent1"><span class="glyph">●</span>Vaccination against meningococcus is particularly critical for patients deficient in properdin and for those deficient in C5, C6, C7, C8, or C9 [<a href="#rid97">97</a>]. (See  <a class="medical medical_review" href="/d/html/3901.html" rel="external">"Meningococcal vaccination in children and adults", section on 'Immunization of persons at increased risk'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The pneumococcal and <em>Haemophilus influenzae b</em> (Hib) conjugated vaccines are also indicated [<a href="#rid98">98,99</a>]. (See  <a class="medical medical_review" href="/d/html/7021.html" rel="external">"Pneumococcal vaccination in adults"</a> and  <a class="medical medical_review" href="/d/html/6022.html" rel="external">"Prevention of <i>Haemophilus influenzae</i> type b infection", section on 'Routine childhood immunization in the United States'</a>.)</p><p></p><p class="headingAnchor" id="H229812616"><span class="h2">Antibiotic prophylaxis</span><span class="headingEndMark"> — </span>Antibiotic prophylaxis may be beneficial for some complement-deficient patients. There are few data about this practice, although controlled studies do suggest that, for terminal complement component deficiencies, injection therapy (<a class="drug drug_general" data-topicid="9092" href="/d/drug information/9092.html" rel="external">benzocaine</a> penicillin injection monthly) or more commonly, oral prophylaxis, is efficacious [<a href="#rid100">100,101</a>]. In most other cases, antibiotic prophylaxis is individualized based upon the frequency, type, and severity of infectious illnesses.</p><p class="headingAnchor" id="H26"><span class="h2">Replacement therapy</span><span class="headingEndMark"> — </span>With rare exceptions, complement component-deficient patients are <strong>not</strong> treated with regular plasma infusions, because this is impractical and, over a lifetime, would be associated with risk of bloodborne diseases [<a href="#rid27">27</a>]. In addition, there is a risk of the development of antibody against the missing component. In the setting of an infection, replacement therapy, such as with fresh frozen plasma (to replace the missing component), is usually not necessary as the patients respond to standard antibiotic therapy. However, in the setting of a slow or inadequate response, infusion therapy is an alternative, although there is very limited experience, and it is not a substitute for more standard treatments.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Atypical hemolytic uremic syndrome (aHUS)</strong> – Infusion of plasma, which contains factors H and I, normalizes the C3 level in patients with a complete deficiency or with a partial deficiency presenting as aHUS and may temporarily alleviate clinical symptoms. However, there are no long-term studies of supplying these regulatory proteins by plasma transfusions. Purified preparations of factor H or factor I are not available for infusion. (See  <a class="medical medical_review" href="/d/html/6084.html" rel="external">"Complement-mediated hemolytic uremic syndrome in children", section on 'Plasma therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other applications of plasma infusions</strong> – A patient with C1q deficiency was treated with fresh frozen plasma infusions over a 10-year period [<a href="#rid102">102</a>]. A small number of cases of C2 deficiency and refractory lupus have been successfully treated with plasma replacement therapy [<a href="#rid103">103</a>]. However, most patients with C2 deficiency and systemic lupus erythematosus (SLE) have mild-to-moderate disease and respond to standard therapies.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Specific therapies</strong> – Specific treatments are available for very few inherited disorders of complement. One available treatment is <a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">eculizumab</a>, a humanized monoclonal antibody that binds to the C5 component of complement and inhibits terminal complement activation. Eculizumab has been approved for treatment of aHUS. It has also been approved for treatment of the acquired complement deficiency disorder paroxysmal nocturnal hemoglobinuria (PNH) and two autoimmune disorders: refractory generalized myasthenia gravis in adults and neuromyelitis optica spectrum disorder. However, patients are expected to be at an increased risk of invasive meningococcal disease as compared with the general population. Case reports describe fatal infection in eculizumab recipients caused by nongroupable meningococcal strains, which rarely cause disease, despite meningococcal vaccination [<a href="#rid104">104,105</a>]. (See  <a class="medical medical_review" href="/d/html/5175.html" rel="external">"Chronic immunotherapy for myasthenia gravis", section on 'Eculizumab'</a> and  <a class="medical medical_review" href="/d/html/134223.html" rel="external">"Neuromyelitis optica spectrum disorder (NMOSD): Treatment and prognosis"</a> and  <a class="medical medical_review" href="/d/html/7163.html" rel="external">"Treatment and prognosis of paroxysmal nocturnal hemoglobinuria", section on 'Eculizumab'</a>.)</p><p></p><p class="headingAnchor" id="H629591682"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112831.html" rel="external">"Society guideline links: Inborn errors of immunity (previously called primary immunodeficiencies)"</a>.)</p><p class="headingAnchor" id="H27"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Homozygous complement deficiencies</strong> – Homozygous deficiencies in complement components are rare. The main clinical manifestations are recurrent infections with encapsulated bacteria, systemic lupus erythematosus (SLE), or both. (See <a class="local">'Deficiencies in an integral component of the activating cascades'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classical pathway components:</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Deficiencies in the early components of the classical complement pathway (ie, C1q, C1r, C1s, C4, and C2) predispose patients to autoimmune disorders, particularly SLE. Recurrent infections may also be seen. (See <a class="local">'C1 deficiency'</a> above and <a class="local">'C4 deficiency'</a> above and <a class="local">'C2 deficiency'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Deficiencies in late components (C3-C9) of the classical complement pathway predispose patients to recurrent infections, especially pneumococcal and <em>Haemophilus influenzae</em> (with C3 deficiency) and neisserial infections (with C5, C6, C7, C8, or C9 deficiency). (See <a class="local">'C3 deficiency'</a> above and <a class="local">'C5-C9 deficiency'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening with CH50</strong> – The total hemolytic complement (THC or CH50) assay is an effective screening test for a complete deficiency of a component of the classical pathway. Complete deficiency generally yields a very low or undetectable CH50 value (with the exception of complete C9 deficiency). Individuals with a heterozygous component deficiency are usually healthy and have normal CH50 values. (See <a class="local">'Screening CH50 and interpretation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening with AH50</strong> – The alternative pathway (AH50) assay is a screen for deficiencies in properdin, factor B, and factor D. Properdin is the most common component of the alternative pathway to be deficient. Properdin deficiency is X linked and presents in males as a familial predisposition to neisserial infections, especially meningitis. Inherited defects in factors D and B have only been described in a few case reports. (See <a class="local">'Alternative pathway deficiencies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Deficiencies in regulatory proteins</strong> – Deficiencies and defects in complement regulatory proteins can lead to specific disorders resulting from unregulated activity of the alternative pathway. Clinically important deficiencies/defects of complement regulatory proteins include those of C1 inhibitor, factor H, factor I, membrane cofactor protein (MCP), complement receptor 3 (CR3), decay-accelerating factor (DAF), and CD59. (See <a class="local">'Abnormalities in regulatory proteins'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Principles of management</strong> – The management of complement-deficient patients primarily involves education of the patient in vigilance for early signs of infection and vaccination against the organisms to which the patient is susceptible. (See <a class="local">'Care of the complement-deficient patient'</a> above.)</p><p></p><p class="headingAnchor" id="H145331402"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges E Richard Stiehm, MD, who contributed as a Section Editor to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Schröder-Braunstein J, Kirschfink M. Complement deficiencies and dysregulation: Pathophysiological consequences, modern analysis, and clinical management. Mol Immunol 2019; 114:299.</a></li><li><a class="nounderline abstract_t">Tangye SG, Al-Herz W, Bousfiha A, et al. Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol 2022; 42:1473.</a></li><li><a class="nounderline abstract_t">Botto M, Kirschfink M, Macor P, et al. Complement in human diseases: Lessons from complement deficiencies. Mol Immunol 2009; 46:2774.</a></li><li><a class="nounderline abstract_t">Grumach AS, Kirschfink M. Are complement deficiencies really rare? Overview on prevalence, clinical importance and modern diagnostic approach. Mol Immunol 2014; 61:110.</a></li><li class="breakAll">Pettigrew HD, Teuber SS, Gershwin ME. Clinical significance of complement deficiencies. In: Annals of the New York Academy of Science, Shoenfeld Y, Gershwin ME (Eds), Blackwell Publishing, Boston 2009. p.108.</li><li><a class="nounderline abstract_t">Figueroa JE, Densen P. Infectious diseases associated with complement deficiencies. Clin Microbiol Rev 1991; 4:359.</a></li><li><a class="nounderline abstract_t">O'Neil KM. Complement deficiency. Clin Rev Allergy Immunol 2000; 19:83.</a></li><li><a class="nounderline abstract_t">Barilla-LaBarca ML, Gioffrè D, Zanichelli A, et al. Acquired C1 esterase inhibitor deficiency in two patients presenting with a lupus-like syndrome and anticardiolipin antibodies. Arthritis Rheum 2002; 47:223.</a></li><li><a class="nounderline abstract_t">Pickering MC, Botto M, Taylor PR, et al. Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv Immunol 2000; 76:227.</a></li><li><a class="nounderline abstract_t">Wen L, Atkinson JP, Giclas PC. Clinical and laboratory evaluation of complement deficiency. J Allergy Clin Immunol 2004; 113:585.</a></li><li><a class="nounderline abstract_t">Colten HR, Rosen FS. Complement deficiencies. Annu Rev Immunol 1992; 10:809.</a></li><li><a class="nounderline abstract_t">Roberts AL, Thomas ER, Bhosle S, et al. Resequencing the susceptibility gene, ITGAM, identifies two functionally deleterious rare variants in systemic lupus erythematosus cases. Arthritis Res Ther 2014; 16:R114.</a></li><li><a class="nounderline abstract_t">Fossati-Jimack L, Ling GS, Cortini A, et al. Phagocytosis is the main CR3-mediated function affected by the lupus-associated variant of CD11b in human myeloid cells. PLoS One 2013; 8:e57082.</a></li><li><a class="nounderline abstract_t">Leffler J, Bengtsson AA, Blom AM. The complement system in systemic lupus erythematosus: an update. Ann Rheum Dis 2014; 73:1601.</a></li><li><a class="nounderline abstract_t">Truedsson L, Bengtsson AA, Sturfelt G. Complement deficiencies and systemic lupus erythematosus. Autoimmunity 2007; 40:560.</a></li><li><a class="nounderline abstract_t">Lipsker D, Hauptmann G. Cutaneous manifestations of complement deficiencies. Lupus 2010; 19:1096.</a></li><li class="breakAll">Atkinson JP, Yu CY. The complement system in systemic lupus erythematosus. In: Systemic Lupus Erythematosus, Basic, Applied and Clinical Aspects, 1st ed, Tsokos G (Ed), Academic Press, London 2016. p.81.</li><li><a class="nounderline abstract_t">Lintner KE, Wu YL, Yang Y, et al. Early Components of the Complement Classical Activation Pathway in Human Systemic Autoimmune Diseases. Front Immunol 2016; 7:36.</a></li><li><a class="nounderline abstract_t">Seddon JM, Yu Y, Miller EC, et al. Rare variants in CFI, C3 and C9 are associated with high risk of advanced age-related macular degeneration. Nat Genet 2013; 45:1366.</a></li><li><a class="nounderline abstract_t">Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013; 368:2169.</a></li><li><a class="nounderline abstract_t">Karpman D, Tati R. Complement activation in thrombotic microangiopathy. Hamostaseologie 2013; 33:96.</a></li><li><a class="nounderline abstract_t">Noris M, Mescia F, Remuzzi G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol 2012; 8:622.</a></li><li><a class="nounderline abstract_t">Kerr H, Richards A. Complement-mediated injury and protection of endothelium: lessons from atypical haemolytic uraemic syndrome. Immunobiology 2012; 217:195.</a></li><li><a class="nounderline abstract_t">Kavanagh D, Goodship TH, Richards A. Atypical hemolytic uremic syndrome. Semin Nephrol 2013; 33:508.</a></li><li><a class="nounderline abstract_t">Wu YL, Yang Y, Chung EK, et al. Phenotypes, genotypes and disease susceptibility associated with gene copy number variations: complement C4 CNVs in European American healthy subjects and those with systemic lupus erythematosus. Cytogenet Genome Res 2008; 123:131.</a></li><li><a class="nounderline abstract_t">Schur PH, Marcus-Bagley D, Awdeh Z, et al. The effect of ethnicity on major histocompatibility complex complement allotypes and extended haplotypes in patients with systemic lupus erythematosus. Arthritis Rheum 1990; 33:985.</a></li><li><a class="nounderline abstract_t">Ram S, Lewis LA, Rice PA. Infections of people with complement deficiencies and patients who have undergone splenectomy. Clin Microbiol Rev 2010; 23:740.</a></li><li><a class="nounderline abstract_t">Atkinson JP, Gorman JC, Curd J, et al. Cold dependent activation of complement in systemic lupus erythematosus. A unique cause for a discrepancy between clinical and laboratory parameters. Arthritis Rheum 1981; 24:592.</a></li><li><a class="nounderline abstract_t">Khajoee V, Ihara K, Kira R, et al. Founder effect of the C9 R95X mutation in Orientals. Hum Genet 2003; 112:244.</a></li><li><a class="nounderline abstract_t">Kang HJ, Kim HS, Lee YK, Cho HC. High incidence of complement C9 deficiency in Koreans. Ann Clin Lab Sci 2005; 35:144.</a></li><li><a class="nounderline abstract_t">Boteva L, Morris DL, Cortés-Hernández J, et al. Genetically determined partial complement C4 deficiency states are not independent risk factors for SLE in UK and Spanish populations. Am J Hum Genet 2012; 90:445.</a></li><li><a class="nounderline abstract_t">Wouters D, van Schouwenburg P, van der Horst A, et al. High-throughput analysis of the C4 polymorphism by a combination of MLPA and isotype-specific ELISA's. Mol Immunol 2009; 46:592.</a></li><li><a class="nounderline abstract_t">Margery-Muir AA, Wetherall JD, Castley AS, et al. Establishment of gene copy number-specific normal ranges for serum C4 and its utility for interpretation in patients with chronically low serum C4 concentrations. Arthritis Rheumatol 2014; 66:2512.</a></li><li><a class="nounderline abstract_t">Triebwasser MP, Roberson ED, Yu Y, et al. Rare Variants in the Functional Domains of Complement Factor H Are Associated With Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci 2015; 56:6873.</a></li><li><a class="nounderline abstract_t">Ramsey-Goldman R, Alexander RV, Conklin J, et al. A Multianalyte Assay Panel With Cell-Bound Complement Activation Products Predicts Transition of Probable Lupus to American College of Rheumatology-Classified Lupus. ACR Open Rheumatol 2021; 3:116.</a></li><li><a class="nounderline abstract_t">Arriens C, Alexander RV, Narain S, et al. Cell-bound complement activation products associate with lupus severity in SLE. Lupus Sci Med 2020; 7.</a></li><li><a class="nounderline abstract_t">Zhang S, Wang S, Li Q, et al. Capillary leak syndrome in children with C4A-deficiency undergoing cardiac surgery with cardiopulmonary bypass: a double-blind, randomised controlled study. Lancet 2005; 366:556.</a></li><li><a class="nounderline abstract_t">Jönsson G, Truedsson L, Sturfelt G, et al. Hereditary C2 deficiency in Sweden: frequent occurrence of invasive infection, atherosclerosis, and rheumatic disease. Medicine (Baltimore) 2005; 84:23.</a></li><li><a class="nounderline abstract_t">Hauck F, Lee-kirsch MA, Aust D, et al. Complement C2 deficiency disarranging innate and adaptive humoral immune responses in a pediatric patient: treatment with rituximab. Arthritis Care Res (Hoboken) 2011; 63:454.</a></li><li><a class="nounderline abstract_t">Ingels H, Schejbel L, Lundstedt AC, et al. Immunodeficiency among children with recurrent invasive pneumococcal disease. Pediatr Infect Dis J 2015; 34:644.</a></li><li><a class="nounderline abstract_t">Glass D, Raum D, Gibson D, et al. Inherited deficiency of the second component of complement. Rheumatic disease associations. J Clin Invest 1976; 58:853.</a></li><li><a class="nounderline abstract_t">Miller EC, Chase NM, Densen P, et al. Autoantibody stabilization of the classical pathway C3 convertase leading to C3 deficiency and Neisserial sepsis: C4 nephritic factor revisited. Clin Immunol 2012; 145:241.</a></li><li><a class="nounderline abstract_t">Paixão-Cavalcante D, López-Trascasa M, Skattum L, et al. Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation. Kidney Int 2012; 82:1084.</a></li><li><a class="nounderline abstract_t">López-Lera A, Garrido S, de la Cruz RM, et al. Molecular characterization of three new mutations causing C5 deficiency in two non-related families. Mol Immunol 2009; 46:2340.</a></li><li><a class="nounderline abstract_t">Parham KL, Roberts A, Thomas A, et al. Prevalence of mutations leading to complete C6 deficiency (C6Q0) in the Western Cape, South Africa and detection of novel mutations leading to C6Q0 in an Irish family. Mol Immunol 2007; 44:2756.</a></li><li><a class="nounderline abstract_t">Zhu Z, Atkinson TP, Hovanky KT, et al. High prevalence of complement component C6 deficiency among African-Americans in the south-eastern USA. Clin Exp Immunol 2000; 119:305.</a></li><li><a class="nounderline abstract_t">Rameix-Welti MA, Régnier CH, Bienaimé F, et al. Hereditary complement C7 deficiency in nine families: subtotal C7 deficiency revisited. Eur J Immunol 2007; 37:1377.</a></li><li><a class="nounderline abstract_t">Barroso S, Rieubland C, José álvarez A, et al. Molecular defects of the C7 gene in two patients with complement C7 deficiency. Immunology 2006; 118:257.</a></li><li><a class="nounderline abstract_t">Chiang YC, Shyur SD, Huang LH, et al. Deficiency of the seventh component of complement in a Taiwanese boy. J Formos Med Assoc 2006; 105:770.</a></li><li><a class="nounderline abstract_t">Pickering MC, Macor P, Fish J, et al. Complement C1q and C8beta deficiency in an individual with recurrent bacterial meningitis and adult-onset systemic lupus erythematosus-like illness. Rheumatology (Oxford) 2008; 47:1588.</a></li><li><a class="nounderline abstract_t">Kojima T, Horiuchi T, Nishizaka H, et al. Genetic basis of human complement C8 alpha-gamma deficiency. J Immunol 1998; 161:3762.</a></li><li><a class="nounderline abstract_t">Tedesco F, Roncelli L, Petersen BH, et al. Two distinct abnormalities in patients with C8 alpha-gamma deficiency. Low level of C8 beta chain and presence of dysfunctional C8 alpha-gamma subunit. J Clin Invest 1990; 86:884.</a></li><li><a class="nounderline abstract_t">Manian FA, Alame D. Case records of the Massachusetts General Hospital. Case 11-2015. A 28-year-old woman with headache, fever, and a rash. N Engl J Med 2015; 372:1454.</a></li><li><a class="nounderline abstract_t">Audemard-Verger A, Descloux E, Ponard D, et al. Infections Revealing Complement Deficiency in Adults: A French Nationwide Study Enrolling 41 Patients. Medicine (Baltimore) 2016; 95:e3548.</a></li><li><a class="nounderline abstract_t">Nishizaka H, Horiuchi T, Zhu ZB, et al. Genetic bases of human complement C7 deficiency. J Immunol 1996; 157:4239.</a></li><li><a class="nounderline abstract_t">Thomas AD, Orren A, Connaughton J, et al. Characterization of a large genomic deletion in four Irish families with C7 deficiency. Mol Immunol 2012; 50:57.</a></li><li><a class="nounderline abstract_t">Barroso S, López-Trascasa M, Merino D, et al. C7 deficiency and meningococcal infection susceptibility in two spanish families. Scand J Immunol 2010; 72:38.</a></li><li><a class="nounderline abstract_t">Kuijpers TW, Nguyen M, Hopman CT, et al. Complement factor 7 gene mutations in relation to meningococcal infection and clinical recurrence of meningococcal disease. Mol Immunol 2010; 47:671.</a></li><li><a class="nounderline abstract_t">Späth PJ, Sjöholm AG, Fredrikson GN, et al. Properdin deficiency in a large Swiss family: identification of a stop codon in the properdin gene, and association of meningococcal disease with lack of the IgG2 allotype marker G2m(n). Clin Exp Immunol 1999; 118:278.</a></li><li><a class="nounderline abstract_t">Bathum L, Hansen H, Teisner B, et al. Association between combined properdin and mannose-binding lectin deficiency and infection with Neisseria meningitidis. Mol Immunol 2006; 43:473.</a></li><li><a class="nounderline abstract_t">Fijen CA, van den Bogaard R, Schipper M, et al. Properdin deficiency: molecular basis and disease association. Mol Immunol 1999; 36:863.</a></li><li><a class="nounderline abstract_t">Fijen CA, Kuijper EJ, te Bulte MT, et al. Assessment of complement deficiency in patients with meningococcal disease in The Netherlands. Clin Infect Dis 1999; 28:98.</a></li><li><a class="nounderline abstract_t">Sprong T, Roos D, Weemaes C, et al. Deficient alternative complement pathway activation due to factor D deficiency by 2 novel mutations in the complement factor D gene in a family with meningococcal infections. Blood 2006; 107:4865.</a></li><li><a class="nounderline abstract_t">Schejbel L, Rosenfeldt V, Marquart H, et al. Properdin deficiency associated with recurrent otitis media and pneumonia, and identification of male carrier with Klinefelter syndrome. Clin Immunol 2009; 131:456.</a></li><li><a class="nounderline abstract_t">Biesma DH, Hannema AJ, van Velzen-Blad H, et al. A family with complement factor D deficiency. J Clin Invest 2001; 108:233.</a></li><li><a class="nounderline abstract_t">Slade C, Bosco J, Unglik G, et al. Deficiency in complement factor B. N Engl J Med 2013; 369:1667.</a></li><li><a class="nounderline abstract_t">Sallenbach S, Thiel S, Aebi C, et al. Serum concentrations of lectin-pathway components in healthy neonates, children and adults: mannan-binding lectin (MBL), M-, L-, and H-ficolin, and MBL-associated serine protease-2 (MASP-2). Pediatr Allergy Immunol 2011; 22:424.</a></li><li><a class="nounderline abstract_t">Endo Y, Matsushita M, Fujita T. The role of ficolins in the lectin pathway of innate immunity. Int J Biochem Cell Biol 2011; 43:705.</a></li><li><a class="nounderline abstract_t">Selman L, Hansen S. Structure and function of collectin liver 1 (CL-L1) and collectin 11 (CL-11, CL-K1). Immunobiology 2012; 217:851.</a></li><li><a class="nounderline abstract_t">Rooryck C, Diaz-Font A, Osborn DP, et al. Mutations in lectin complement pathway genes COLEC11 and MASP1 cause 3MC syndrome. Nat Genet 2011; 43:197.</a></li><li><a class="nounderline abstract_t">Degn SE, Thiel S, Jensenius JC. New perspectives on mannan-binding lectin-mediated complement activation. Immunobiology 2007; 212:301.</a></li><li><a class="nounderline abstract_t">Stengaard-Pedersen K, Thiel S, Gadjeva M, et al. Inherited deficiency of mannan-binding lectin-associated serine protease 2. N Engl J Med 2003; 349:554.</a></li><li><a class="nounderline abstract_t">Schlapbach LJ, Aebi C, Otth M, et al. Deficiency of mannose-binding lectin-associated serine protease-2 associated with increased risk of fever and neutropenia in pediatric cancer patients. Pediatr Infect Dis J 2007; 26:989.</a></li><li><a class="nounderline abstract_t">Munthe-Fog L, Hummelshøj T, Honoré C, et al. Immunodeficiency associated with FCN3 mutation and ficolin-3 deficiency. N Engl J Med 2009; 360:2637.</a></li><li><a class="nounderline abstract_t">Michalski M, Świerzko AS, Pągowska-Klimek I, et al. Primary Ficolin-3 deficiency--Is it associated with increased susceptibility to infections? Immunobiology 2015; 220:711.</a></li><li><a class="nounderline abstract_t">Walport MJ, Lachmann PJ. Erythrocyte complement receptor type 1, immune complexes, and the rheumatic diseases. Arthritis Rheum 1988; 31:153.</a></li><li><a class="nounderline abstract_t">Jodele S, Licht C, Goebel J, et al. Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Blood 2013; 122:2003.</a></li><li><a class="nounderline abstract_t">Richards A, Kavanagh D, Atkinson JP. Inherited complement regulatory protein deficiency predisposes to human disease in acute injury and chronic inflammatory statesthe examples of vascular damage in atypical hemolytic uremic syndrome and debris accumulation in age-related macular degeneration. Adv Immunol 2007; 96:141.</a></li><li><a class="nounderline abstract_t">Jokiranta TS, Zipfel PF, Fremeaux-Bacchi V, et al. Where next with atypical hemolytic uremic syndrome? Mol Immunol 2007; 44:3889.</a></li><li><a class="nounderline abstract_t">Liszewski MK, Atkinson JP. Complement regulators in human disease: lessons from modern genetics. J Intern Med 2015; 277:294.</a></li><li><a class="nounderline abstract_t">Avila Bernabeu AI, Cavero Escribano T, Cao Vilarino M. Atypical Hemolytic Uremic Syndrome: New Challenges in the Complement Blockage Era. Nephron 2020; 144:537.</a></li><li><a class="nounderline abstract_t">Java A, Pozzi N, Love-Gregory LD, et al. A Multimodality Approach to Assessing Factor I Genetic Variants in Atypical Hemolytic Uremic Syndrome. Kidney Int Rep 2019; 4:1007.</a></li><li><a class="nounderline abstract_t">Fuchs A, Atkinson JP, Fremeaux-Bacchi V, Kemper C. CD46-induced human Treg enhance B-cell responses. Eur J Immunol 2009; 39:3097.</a></li><li><a class="nounderline abstract_t">Wu X, Spitzer D, Mao D, et al. Membrane protein Crry maintains homeostasis of the complement system. J Immunol 2008; 181:2732.</a></li><li><a class="nounderline abstract_t">van de Ven JP, Nilsson SC, Tan PL, et al. A functional variant in the CFI gene confers a high risk of age-related macular degeneration. Nat Genet 2013; 45:813.</a></li><li><a class="nounderline abstract_t">Zhan X, Larson DE, Wang C, et al. Identification of a rare coding variant in complement 3 associated with age-related macular degeneration. Nat Genet 2013; 45:1375.</a></li><li><a class="nounderline abstract_t">Helgason H, Sulem P, Duvvari MR, et al. A rare nonsynonymous sequence variant in C3 is associated with high risk of age-related macular degeneration. Nat Genet 2013; 45:1371.</a></li><li><a class="nounderline abstract_t">Fakhouri F, Frémeaux-Bacchi V, Noël LH, et al. C3 glomerulopathy: a new classification. Nat Rev Nephrol 2010; 6:494.</a></li><li><a class="nounderline abstract_t">Lesher AM, Song WC. Review: Complement and its regulatory proteins in kidney diseases. Nephrology (Carlton) 2010; 15:663.</a></li><li><a class="nounderline abstract_t">Warwicker P, Goodship TH, Goodship JA. Three new polymorphisms in the human complement factor H gene and promoter region. Immunogenetics 1997; 46:437.</a></li><li><a class="nounderline abstract_t">Haralambous E, Dolly SO, Hibberd ML, et al. Factor H, a regulator of complement activity, is a major determinant of meningococcal disease susceptibility in UK Caucasian patients. Scand J Infect Dis 2006; 38:764.</a></li><li><a class="nounderline abstract_t">Fang CJ, Richards A, Liszewski MK, et al. Advances in understanding of pathogenesis of aHUS and HELLP. Br J Haematol 2008; 143:336.</a></li><li><a class="nounderline abstract_t">Fang CJ, Fremeaux-Bacchi V, Liszewski MK, et al. Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome. Blood 2008; 111:624.</a></li><li><a class="nounderline abstract_t">Crovetto F, Borsa N, Acaia B, et al. The genetics of the alternative pathway of complement in the pathogenesis of HELLP syndrome. J Matern Fetal Neonatal Med 2012; 25:2322.</a></li><li><a class="nounderline abstract_t">Vaught AJ, Braunstein EM, Jasem J, et al. Germline mutations in the alternative pathway of complement predispose to HELLP syndrome. JCI Insight 2018; 3.</a></li><li><a class="nounderline abstract_t">Ozen A, Comrie WA, Ardy RC, et al. CD55 Deficiency, Early-Onset Protein-Losing Enteropathy, and Thrombosis. N Engl J Med 2017; 377:52.</a></li><li><a class="nounderline abstract_t">Platonov AE, Vershinina IV, Kuijper EJ, et al. Long term effects of vaccination of patients deficient in a late complement component with a tetravalent meningococcal polysaccharide vaccine. Vaccine 2003; 21:4437.</a></li><li><a class="nounderline abstract_t">Jönsson G, Lood C, Gullstrand B, et al. Vaccination against encapsulated bacteria in hereditary C2 deficiency results in antibody response and opsonization due to antibody-dependent complement activation. Clin Immunol 2012; 144:214.</a></li><li><a class="nounderline abstract_t">Briere EC, Rubin L, Moro PL, et al. Prevention and control of haemophilus influenzae type b disease: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep 2014; 63:1.</a></li><li><a class="nounderline abstract_t">Fries LF, O'Shea JJ, Frank MM. Inherited deficiencies of complement and complement-related proteins. Clin Immunol Immunopathol 1986; 40:37.</a></li><li><a class="nounderline abstract_t">Potter PC, Frasch CE, van der Sande WJ, et al. Prophylaxis against Neisseria meningitidis infections and antibody responses in patients with deficiency of the sixth component of complement. J Infect Dis 1990; 161:932.</a></li><li><a class="nounderline abstract_t">Mehta P, Norsworthy PJ, Hall AE, et al. SLE with C1q deficiency treated with fresh frozen plasma: a 10-year experience. Rheumatology (Oxford) 2010; 49:823.</a></li><li><a class="nounderline abstract_t">Erlendsson K, Traustadóttir K, Freysdóttir J, et al. Reciprocal changes in complement activity and immune-complex levels during plasma infusion in a C2-deficient SLE patient. Lupus 1993; 2:161.</a></li><li><a class="nounderline abstract_t">McNamara LA, Topaz N, Wang X, et al. High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine. Am J Transplant 2017; 17:2481.</a></li><li><a class="nounderline abstract_t">Nolfi-Donegan D, Konar M, Vianzon V, et al. Fatal Nongroupable Neisseria meningitidis Disease in Vaccinated Patient Receiving Eculizumab. Emerg Infect Dis 2018; 24.</a></li></ol></div><div id="topicVersionRevision">Topic 3962 Version 31.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31421540" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Complement deficiencies and dysregulation: Pathophysiological consequences, modern analysis, and clinical management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35748970" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19481265" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Complement in human diseases: Lessons from complement deficiencies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25037634" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Are complement deficiencies really rare? Overview on prevalence, clinical importance and modern diagnostic approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25037634" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Are complement deficiencies really rare? Overview on prevalence, clinical importance and modern diagnostic approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1889047" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Infectious diseases associated with complement deficiencies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11107496" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Complement deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11954019" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Acquired C1 esterase inhibitor deficiency in two patients presenting with a lupus-like syndrome and anticardiolipin antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11079100" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Systemic lupus erythematosus, complement deficiency, and apoptosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15100659" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Clinical and laboratory evaluation of complement deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1591004" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Complement deficiencies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24886912" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Resequencing the susceptibility gene, ITGAM, identifies two functionally deleterious rare variants in systemic lupus erythematosus cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23451151" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Phagocytosis is the main CR3-mediated function affected by the lupus-associated variant of CD11b in human myeloid cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24845390" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The complement system in systemic lupus erythematosus: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18075790" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Complement deficiencies and systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20693203" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Cutaneous manifestations of complement deficiencies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20693203" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Cutaneous manifestations of complement deficiencies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26913032" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Early Components of the Complement Classical Activation Pathway in Human Systemic Autoimmune Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24036952" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Rare variants in CFI, C3 and C9 are associated with high risk of advanced age-related macular degeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23738544" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23411690" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Complement activation in thrombotic microangiopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22986360" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : STEC-HUS, atypical HUS and TTP are all diseases of complement activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21855165" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Complement-mediated injury and protection of endothelium: lessons from atypical haemolytic uraemic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24161037" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Atypical hemolytic uremic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19287147" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Phenotypes, genotypes and disease susceptibility associated with gene copy number variations: complement C4 CNVs in European American healthy subjects and those with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2369433" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The effect of ethnicity on major histocompatibility complex complement allotypes and extended haplotypes in patients with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20930072" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Infections of people with complement deficiencies and patients who have undergone splenectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7213441" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Cold dependent activation of complement in systemic lupus erythematosus. A unique cause for a discrepancy between clinical and laboratory parameters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12596049" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Founder effect of the C9 R95X mutation in Orientals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15943177" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : High incidence of complement C9 deficiency in Koreans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22387014" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Genetically determined partial complement C4 deficiency states are not independent risk factors for SLE in UK and Spanish populations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19062096" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : High-throughput analysis of the C4 polymorphism by a combination of MLPA and isotype-specific ELISA's.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24757030" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Establishment of gene copy number-specific normal ranges for serum C4 and its utility for interpretation in patients with chronically low serum C4 concentrations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26501415" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Rare Variants in the Functional Domains of Complement Factor H Are Associated With Age-Related Macular Degeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33538130" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : A Multianalyte Assay Panel With Cell-Bound Complement Activation Products Predicts Transition of Probable Lupus to American College of Rheumatology-Classified Lupus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32371480" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Cell-bound complement activation products associate with lupus severity in SLE.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16099291" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Capillary leak syndrome in children with C4A-deficiency undergoing cardiac surgery with cardiopulmonary bypass: a double-blind, randomised controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15643297" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Hereditary C2 deficiency in Sweden: frequent occurrence of invasive infection, atherosclerosis, and rheumatic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20890976" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Complement C2 deficiency disarranging innate and adaptive humoral immune responses in a pediatric patient: treatment with rituximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25831419" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Immunodeficiency among children with recurrent invasive pneumococcal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/965492" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Inherited deficiency of the second component of complement. Rheumatic disease associations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23117396" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Autoantibody stabilization of the classical pathway C3 convertase leading to C3 deficiency and Neisserial sepsis: C4 nephritic factor revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22854646" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19414197" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Molecular characterization of three new mutations causing C5 deficiency in two non-related families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17257682" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Prevalence of mutations leading to complete C6 deficiency (C6Q0) in the Western Cape, South Africa and detection of novel mutations leading to C6Q0 in an Irish family.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10632667" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : High prevalence of complement component C6 deficiency among African-Americans in the south-eastern USA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17407100" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Hereditary complement C7 deficiency in nine families: subtotal C7 deficiency revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16771861" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Molecular defects of the C7 gene in two patients with complement C7 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16959627" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Deficiency of the seventh component of complement in a Taiwanese boy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18682415" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Complement C1q and C8beta deficiency in an individual with recurrent bacterial meningitis and adult-onset systemic lupus erythematosus-like illness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9759902" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Genetic basis of human complement C8 alpha-gamma deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2394837" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Two distinct abnormalities in patients with C8 alpha-gamma deficiency. Low level of C8 beta chain and presence of dysfunctional C8 alpha-gamma subunit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25853750" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Case records of the Massachusetts General Hospital. Case 11-2015. A 28-year-old woman with headache, fever, and a rash.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27175654" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Infections Revealing Complement Deficiency in Adults: A French Nationwide Study Enrolling 41 Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8892662" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Genetic bases of human complement C7 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22206826" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Characterization of a large genomic deletion in four Irish families with C7 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20591074" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : C7 deficiency and meningococcal infection susceptibility in two spanish families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19931914" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Complement factor 7 gene mutations in relation to meningococcal infection and clinical recurrence of meningococcal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10540191" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Properdin deficiency in a large Swiss family: identification of a stop codon in the properdin gene, and association of meningococcal disease with lack of the IgG2 allotype marker G2m(n).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16337490" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Association between combined properdin and mannose-binding lectin deficiency and infection with Neisseria meningitidis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10698340" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Properdin deficiency: molecular basis and disease association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10028078" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Assessment of complement deficiency in patients with meningococcal disease in The Netherlands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16527897" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Deficient alternative complement pathway activation due to factor D deficiency by 2 novel mutations in the complement factor D gene in a family with meningococcal infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19328743" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Properdin deficiency associated with recurrent otitis media and pneumonia, and identification of male carrier with Klinefelter syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11457876" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : A family with complement factor D deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24152280" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Deficiency in complement factor B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21226765" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Serum concentrations of lectin-pathway components in healthy neonates, children and adults: mannan-binding lectin (MBL), M-, L-, and H-ficolin, and MBL-associated serine protease-2 (MASP-2).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21315829" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : The role of ficolins in the lectin pathway of innate immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22475410" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Structure and function of collectin liver 1 (CL-L1) and collectin 11 (CL-11, CL-K1).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21258343" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Mutations in lectin complement pathway genes COLEC11 and MASP1 cause 3MC syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17544815" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : New perspectives on mannan-binding lectin-mediated complement activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12904520" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Inherited deficiency of mannan-binding lectin-associated serine protease 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17984804" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Deficiency of mannose-binding lectin-associated serine protease-2 associated with increased risk of fever and neutropenia in pediatric cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19535802" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Immunodeficiency associated with FCN3 mutation and ficolin-3 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25662573" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Primary Ficolin-3 deficiency--Is it associated with increased susceptibility to infections?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3279961" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Erythrocyte complement receptor type 1, immune complexes, and the rheumatic diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23814021" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17981206" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Inherited complement regulatory protein deficiency predisposes to human disease in acute injury and chronic inflammatory statesthe examples of vascular damage in atypical hemolytic uremic syndrome and debris accumulation in age-related macular degeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17768107" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Where next with atypical hemolytic uremic syndrome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25495259" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Complement regulators in human disease: lessons from modern genetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32950988" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Atypical Hemolytic Uremic Syndrome: New Challenges in the Complement Blockage Era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31312772" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : A Multimodality Approach to Assessing Factor I Genetic Variants in Atypical Hemolytic Uremic Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19784949" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : CD46-induced human Treg enhance B-cell responses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18684964" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Membrane protein Crry maintains homeostasis of the complement system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23685748" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : A functional variant in the CFI gene confers a high risk of age-related macular degeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24036949" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Identification of a rare coding variant in complement 3 associated with age-related macular degeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24036950" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : A rare nonsynonymous sequence variant in C3 is associated with high risk of age-related macular degeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20606628" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : C3 glomerulopathy: a new classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21040161" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Review: Complement and its regulatory proteins in kidney diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9271636" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Three new polymorphisms in the human complement factor H gene and promoter region.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16938729" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Factor H, a regulator of complement activity, is a major determinant of meningococcal disease susceptibility in UK Caucasian patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18691170" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Advances in understanding of pathogenesis of aHUS and HELLP.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17914026" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22594569" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : The genetics of the alternative pathway of complement in the pathogenesis of HELLP syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29563339" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Germline mutations in the alternative pathway of complement predispose to HELLP syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28657829" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : CD55 Deficiency, Early-Onset Protein-Losing Enteropathy, and Thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14505927" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Long term effects of vaccination of patients deficient in a late complement component with a tetravalent meningococcal polysaccharide vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22842196" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Vaccination against encapsulated bacteria in hereditary C2 deficiency results in antibody response and opsonization due to antibody-dependent complement activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24572654" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Prevention and control of haemophilus influenzae type b disease: recommendations of the advisory committee on immunization practices (ACIP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2941192" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Inherited deficiencies of complement and complement-related proteins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2109021" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Prophylaxis against Neisseria meningitidis infections and antibody responses in patients with deficiency of the sixth component of complement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19965977" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : SLE with C1q deficiency treated with fresh frozen plasma: a 10-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8369807" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Reciprocal changes in complement activity and immune-complex levels during plasma infusion in a C2-deficient SLE patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28846836" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30015608" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Fatal Nongroupable Neisseria meningitidis Disease in Vaccinated Patient Receiving Eculizumab.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
